<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225676</url>
  </required_header>
  <id_info>
    <org_study_id>CCTL019BUS03</org_study_id>
    <nct_id>NCT04225676</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With ALL</brief_title>
  <official_title>A Phase II, Open Label, Multi-center Trial to Determine the Efficacy and Safety of Tisagenlecleucel Re-infusion in Pediatric and Adolescent Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B Cell Aplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center Phase II study investigating the efficacy and safety of reinfusion of
      tisagenlecleucel in pediatric and young adult patients with ALL who were treated with
      tisagenlecleucel and experience B cell recovery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 29, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who establish B cell aplasia within 12 months of reinfusion, as measured by circulating B lymphocytes (≥ 50/µL) and presence of CTL019 cells by qPCR in the peripheral blood</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Evaluate the incidence of B cell aplasia after reinfusion of tisagenlecleucel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients who maintain ORR with MRD negativity during 12 months post-reinfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>12 months</time_frame>
    <description>the time from date of tisagenlecleucel reinfusion to the earliest of relapse, treatment failure, or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>12 months</time_frame>
    <description>the time from date of tisagenlecleucel re-infusion to the date of death due to any reason</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>ALL</condition>
  <arm_group>
    <arm_group_label>Tisagenlecleucel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tisagenlecleucel Infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tisagenlecleucel</intervention_name>
    <description>Infusion</description>
    <arm_group_label>Tisagenlecleucel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent must be obtained prior to participation in the study

          -  Must have an additional dose of tisagenlecleucel available

          -  Age up to and including 25 years

          -  Patients must have CD-19+ Leukemia

          -  Patients who were previously treated with tisagenlecleucel and present with evidence
             of B-cell recovery as defined by: Peripheral blood (PB) absolute B lymphocyte count ≥
             50/µL, OR PB B lymphocyte ≥ 10% of the total lymphocytes, OR Peripheral blood absolute
             B lymphocyte count ≥ 200/µL

        Exclusion Criteria:

          -  Prior gene therapy other than tisagenlecleucel

          -  Prior adoptive T cell therapy other than tisagenlecleucel

          -  Active CNS involvement by malignancy

          -  Active or latent hepatitis B or active hepatitis C, or any uncontrolled infection at
             screening

          -  HIV positive test within 8 weeks of screening

        Other protocol-defined Inclusion/Exclusion may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CTL019</keyword>
  <keyword>Kymriah</keyword>
  <keyword>Tisagenlecleucel</keyword>
  <keyword>B-Cell Acute Lymphoblastic Leukemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Young Adult</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_url>https://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

